Borderline resectable pancreatic cancer: questions for the team

Borderline resectable pancreatic cancer is neither a promise of surgery nor a final refusal. It describes a situation in which the possibility of complete removal needs particularly careful assessment. A useful consultation explains which anatomical findings led to that classification and under what conditions the team would reconsider the operative plan.

Clarify the diagnosis and classification

This discussion commonly concerns pancreatic ductal adenocarcinoma. Other tumours arising in the pancreas can follow different treatment pathways. Provide the complete pathology if tissue has been obtained, rather than replacing the diagnosis with the general word “cancer.” If the diagnosis is still being clarified, keep that uncertainty visible in the request.

NCI distinguishes resectable, borderline resectable, locally advanced and metastatic pancreatic disease. Borderline resectability involves relationships with important structures that raise concerns about complete removal. A patient cannot reliably assign that category from one phrase in a CT report. NCI: Pancreatic Cancer Treatment.

Let the surgeon review the original anatomy

The assessment needs original CT or MRI files as well as detailed reports. The relationships to blood vessels and nearby structures matter, along with possible disease elsewhere. Ask whether the existing examination protocol is adequate for the question. A repeat scan should have a defined clinical purpose rather than be an automatic requirement because the patient is travelling from another country.

Keep earlier examinations if treatment has already taken place. In the accompanying timeline, identify systemic-treatment dates, radiation, biopsy and any stent procedure. This helps the team distinguish the original anatomical situation from changes after treatment or another intervention.

Understand a treatment-first proposal

The team may consider systemic or combined treatment before another surgical discussion. Ask whether its purpose is disease control, assessment of tumour behaviour, changing the conditions for resection or a combination of objectives. The regimen and number of stages require an individual clinical decision. Tumour shrinkage cannot be promised to make an operation appropriate.

Identify when reassessment will take place and which information will be required. Request a written explanation of what would support consideration of resection, what might alter the overall treatment objective and which specialists will participate. A conditional future step is different from a confirmed operation date, and the travel plan should preserve that distinction.

Assess readiness for a sequence of care

Nutritional intake, weight loss, jaundice, pain, other illnesses and everyday independence can all matter to planning. Provide documentation of any biliary stent or drainage procedure. Its ongoing care needs to be connected to the oncology pathway. The clinician determines which problems need attention before travel or the next treatment stage.

A sudden deterioration should not wait for an overseas multidisciplinary meeting. For a planned review, discuss acceptable waiting time with the current doctor. A coordinator can organize records and appointments but does not determine whether postponing treatment is medically safe.

Make differing resectability opinions comparable

Check that both specialists reviewed the same imaging at the same point in the illness. Ask whether the difference concerns anatomical interpretation, a possible vascular component, disease beyond the pancreas or the patient’s health. A promise to perform a complex operation is not more persuasive unless the expected benefit and risks are explained.

The guides to an oncology second opinion and comparing treatment plans help structure these questions. The conclusion should identify a confirmed immediate step, conditions for reassessment and the limits of the preliminary opinion. Those details provide a practical basis for planning care in Turkey and obtaining a stage-specific cost estimate without treating a possible later operation as a certainty.